Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Prulacabtagene Leucel · ADI-001

Cell therapy (CAR-T) · Kills target cells, directed at CD20 (MS4A1) · developed by Adicet Therapeutics

Phase 1 Most advanced trial
ACET Developer
1 Registered trials

What is Prulacabtagene Leucel?

Prulacabtagene leucel is an allogeneic gamma delta CAR-T cell therapy engineered to target CD20-expressing cells. Upon administration, it binds CD20 on tumor cells, induces pro-inflammatory cytokine secretion, and mediates cell lysis. It is being studied in rheumatoid arthritis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
ADI-001
Drug type
Cell therapy (CAR-T)
Targets
CD20 (MS4A1) (antigen)
Mechanism
Kills target cells, directed at CD20 (MS4A1)
Pathways
immune_activation, cytokine_secretion
Therapy area
Immunology
Developer
Adicet Therapeutics (ACET)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
PA43J5W22U

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07100873 Phase 1 Rheumatoid Arthritis (RA) Recruiting ACET

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Rheumatoid Arthritis (RA)

Other drugs acting on MS4A1

AZD5492 Phase 1/2 Imvotamab Phase 1/2 Odronextamab Phase 2/3 TL011 Phase 1

More from Adicet Therapeutics

ADI-212 Phase 1/2 ADI-270 Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ACET page.

Follow ACET, the company behind Prulacabtagene Leucel

See ACET's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ACET catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.